[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365953-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365953-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-review-of-human-papillomavirus-prevalence-and-cervical-cancer-in-myanmar-review-article","A Review of Human Papillomavirus Prevalence and Cervical Cancer in Myanmar - Review Article","","Myanmar faces one of the highest cervical cancer incidence and mortality burdens in Asia, with limited screening and treatment capacity restricting prevention and timely care. This review synthesizes evidence on cervical cancer epidemiology in Myanmar, including human papillomavirus (HPV) burden, precancerous cervical lesions, key co-factors, and associated cancer outcomes. Systematic review methods based on observational studies summarize registry, meta-analysis, and database findings through May 31, 2024.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-review-of-human-papillomavirus-prevalence-and-cervical-cancer-in-myanmar-review-article/365953/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-review-of-human-papillomavirus-prevalence-and-cervical-cancer-in-myanmar-review-article/365953.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the review in the document?","Question",{"text":63,"@type":64},"To synthesize evidence on the epidemiology of cervical cancer in Myanmar, including HPV prevalence, precancerous lesions, key co-factors, and the cervical cancer burden in the country.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the studies selected and what search time range was used?",{"text":68,"@type":64},"An approach based on the Joanna Briggs Institute for systematic review of observational epidemiological studies was used, searching Embase, Global Health, Medline, and local databases up to May 31, 2024.",{"name":70,"@type":61,"acceptedAnswer":71},"What cervical cancer incidence and HPV prevalence estimates are reported for Myanmar?",{"text":72,"@type":64},"Cancer registries reported age-standardized incidence rates of 19.3 per 100,000 females in 2018 (Nay Pyi Taw) and 14.1 per 100,000 females during 2013–2017 (Yangon). Meta-analyses estimated HPV prevalence as 4% among community-based general female populations (18–65) and 11% among outpatient clinic screening.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365953,1790202467,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Journal of Epidemiology and Global Health (2025) 15:89  \n[https://doi.org/10.1007/s44197-025-00436-4](https://doi.org/10.1007/s44197-025-00436-4)  \nREVIEW ARTICLE  \nA Review of Human Papillomavirus Prevalence and Cervical Cancer in Myanmar  \nTay Za Kyi Win1 · Kate Simms1 · Myint Myint Thinn2 · Khaing NweTin3 · Soe Aung4 · Eleonora Feletto5 · Deborah Bateson6 · Karen Canfell1  \nReceived: 18 March 2025 / Accepted: 18 June 2025 © The Author(s) 2025  \nAbstract  \nBackground Myanmar is estimated to have one of the highest cervical cancer incidence and mortality rates in Asia. There have been limited screening and treatment services for cervical cancer in Myanmar. In this context, to support cervical cancer elimination, understanding the current burden of cervical cancer in the country is crucial. This review aims to synthesize the evidence on the epidemiology of cervical cancer in Myanmar.  \nMethods We used the Joanna Briggs Institute approach for systematic review of observational epidemiological studies to conduct a comprehensive review of burden of human papillomavirus (HPV), precancerous cervical lesions, key co-factors and cervical cancer in Myanmar. Embase, Global Health, Medline, and local databases were searched to May 31, 2024. Results Regional population-based cancer registries from Nay Pyi Taw and Yangon reported age-standardized incidence rates of cervical cancer of 19.3 (in 2018) and 14.1 (during 2013–2017) per 100 000 females, respectively. Meta-analyses were conducted to estimate HPV prevalence among the general female population (18–65 years) as 4%[95% Confidence Interval (CI): 3–5%] in the community-based and 11%[95% CI: (4–21%)] in outpatient clinic screening. Among HIVpositive women, HPV prevalence was reported at 30.1% . The most common HPV types in HPV-positive cervical cancers were HPV 16 (60–85.7%) and HPV 18 (14.8–20%). The prevalence of key co-factors included HIV infection (0.7% in the general female population and 8.3% in female sex workers), tobacco use in females (smoking: 8.4% and smokeless: 24.1%), high parity (4.99 births per married woman) and early aged pregnancy (33 births per 1000 adolescent females) .  \nConclusions The cervical cancer incidence rates reported from two regional cancer registries in Myanmar are high relative to those reported in countries across Asia. An estimated one in nine to one in 25 women in Myanmar is infected with HPV, which is broadly concordant with regional estimates. A high prevalence of key co-factors for cervical cancer, combined with limited screening and treatment services, may increase the risk of progression to invasive cancers among HPV infected women. Consequently, Myanmar is likely to bear a substantial burden of cervical cancer.  \nKeywords Cervical cancer · Burden of disease · Human papillomavirus · Myanmar  \n􀀍  \n1  \n2  \n3  \nTay Za Kyi Win  \n[twin0929@uni.sydney.edu.au](twin0929@uni.sydney.edu.au)  \nSchool of Public Health, The University of Sydney, Camperdown, NSW, Australia  \nDepartment of Gynaecologic Oncology, Central Women Hospital, Yangon, Myanmar  \nMaternal and Reproductive Health Division, Department of Public Health, Nay Pyi Taw, Myanmar  \n4 Department of Medical Oncology, University of Medicine, Yangon, Myanmar  \n5 The Daffodil Centre, A Joint Venture between Cancer Council NSW and the University of Sydney, Sydney, NSW, Australia  \n6 School of Medicine, The University of Sydney, Camperdown, NSW, Australia  \n1 3  \n1 Introduction  \nCervical cancer is the fourth most diagnosed cancer type and the fourth leading cause of cancer death in women worldwide [1] . There are inequities in the burden of cervical cancer worldwide with about 90% of new cases and deaths occurring in low and middle-income countries (LMICs) [2] . Almost all cervical cancer is caused by persistent human papillomavirus (HPV) infection, which is influenced by several important co-factors, including HIV infection, tobacco smoking, use of oral contraceptive pills, multiparity and early ag","cbCaidiJNVJJEMmg","https://ap.wps.com/l/cbCaidiJNVJJEMmg","pdf",1895942,"English","# Abstract\n# Introduction\n## Global cervical cancer burden\n## HPV, co-factors, and elimination strategy\n## Myanmar context and screening limitations","[{\"question\":\"What is the main purpose of the review in the document?\",\"answer\":\"To synthesize evidence on the epidemiology of cervical cancer in Myanmar, including HPV prevalence, precancerous lesions, key co-factors, and the cervical cancer burden in the country.\"},{\"question\":\"How were the studies selected and what search time range was used?\",\"answer\":\"An approach based on the Joanna Briggs Institute for systematic review of observational epidemiological studies was used, searching Embase, Global Health, Medline, and local databases up to May 31, 2024.\"},{\"question\":\"What cervical cancer incidence and HPV prevalence estimates are reported for Myanmar?\",\"answer\":\"Cancer registries reported age-standardized incidence rates of 19.3 per 100,000 females in 2018 (Nay Pyi Taw) and 14.1 per 100,000 females during 2013–2017 (Yangon). Meta-analyses estimated HPV prevalence as 4% among community-based general female populations (18–65) and 11% among outpatient clinic screening.\"}]","A Review of Human Papillomavirus Prevalence and Cervical Cancer in Myanmar - Review Article | PDF",1790163091,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69a3a16afab86b3c3127d512e93b920e.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cb758cd6fee69e30bea8f407bba309c.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/677f8a965903c06a24e3732a94f9f0a4.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06cdec8d1d7a91dc031302fea4db65e0.webp",980,1301]